Skip to main content

Table 4 Comparison of demographics and disease manifestations in MPO-ANCA-positive and PR3-ANCA-positive patients

From: Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

 

MPO-ANCA

PR3-ANCA

P value

(n = 125)

(n = 13)

Male/female

47/78

6/7

0.56

Mean (median) age (years)

70.0 ± 1.04 (73)

61.3 ± 3.2 (61)

0.012

Serum creatinine (mg/dl)

1.94 ± 0.17

1.22 ± 0.53

0.19

Interstitial lung disease

57 (45.6)

0 (0)

0.0015

Alveolar haemorrhage

11 (8.8)

1 (7.7)

0.89

Disease severity

0.26

 Localised

2 (1.6)

1 (7.7)

 

 Early systemic

33 (26.4)

2 (15.4)

 Generalised

68 (54.4)

8 (61.5)

 Severe

22 (17.6)

2 (15.4)

General performancea

0.26

 0/1/2/3/4

16/44/26/31/8

4/6/1/2/0

 

BVASb

 BVAS

17.5 ± 0.71

17.5 ± 2.2

0.99

 General

95 (76.0)

10 (76.9)

0.94

 Cutaneous

30 (24.0)

0 (0)

0.046

 Mucous membranes/eyes

16 (12.8)

4 (30.8)

0.08

 Ear, nose, and throat

22 (17.6)

12 (92.3)

<0.0001

 Chest

49 (39.2)

7 (53.9)

0.31

 Cardiovascular

8 (6.4)

2 (15.4)

0.23

 Abdominal

2 (1.6)

0 (0)

0.65

 Renal

98 (78.4)

6 (46.2)

0.010

 Nervous system

55 (44.0)

4 (30.8)

0.36

  1. Values expressed as mean ± standard error or number (percentage) unless otherwise noted. Five patients who were double-positive for both ANCAs were excluded from this analysis. ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; PR3, proteinase-3. aGeneral performance was categorised according to the World Health Organization performance status except category 5 (death). bDisease activity and patterns of organ involvement were defined by the BVAS 2003 scoring system.
Back to article page